1-19 of 19 Products & Services
Designed for use with PerkinElmer's IVIS® optical imaging systems, Living Image enables you to analyze 2D and 3D optical imaging data from your animal models with ease. With features such as wizard guidance for acquisition parameter setup and co-registration with other imaging modalities, Living Image allows you to seamlessly capture, visualize and analyze your 2D or 3D optical data to facilitate your drug discovery & development and biology research.
Living Image in vivo software is available for the IVIS Lumina and IVIS Spectrum Series.
1-9 of 9 Business Insights
Cancer chemotherapy can produce severe side effects such as suppression of immune function and damage to heart muscle, gastrointestinal tract, and liver. If serious enough, tissue injury can be a major reason for late stage termination of drug discovery research projects, so it is becoming more important to integrate safety/toxicology assessments earlier in the drug development process. There are a variety of traditional serum markers, tailored mechanistically to specific tissues, however there are no current non-invasive assessment tools that are capable of looking broadly at in situ biological changes in target and non-target tissue induced by chemical insult.
Targeted cancer therapy aims to block key signaling pathways that are critical for tumor cell growth and survival. The blockage eventually results in cell death via apoptosis and eventual tumor growth suppression. This strategy has proven to be quite effective, and the FDA has approved several targeted therapeutics in the past decade. Encouraged by the success in clinical development, many academic and pharmaceutical researchers are in active pursuit of improved next generation targeted anti-cancer drugs. As a result, many new chemical and biological entities are emerging from initial screening of in vitro, in vitro and/or in silico selection processes. From the perspective of drug development, it poses a great challenge for the next stage of in vivo validation and demands a robust, accurate, and efficient method for assessment of these candidates in living animal models.
With the potential to treat a wide range of disease, from organ damage to congenital defects, stem cell research and tissue engineering form the underlying basis of regenerative medicine. Significant advances in the science of skin regeneration, for example, have now made it possible to develop and grow artificial skin grafts in a lab for treatment of burn victims. Other therapeutic applications include the use of stem cells to treat and repair central nervous system diseases such as ischemia and cerebral palsy, cardiovascular diseases, as well as autoimmune diseases including type I diabetes.
Bone erosion is a pathological condition characterized by breaks in the cortical bone surface and loss of the adjacent trabecular bone. Several pathological processes can lead to bone erosion, including malignant tumors, abnormal metabolic processes such as hyperparathyroidism, and chronic inflammatory diseases such as rheumatoid arthritis. In clinical settings, bone erosion is routinely detected using X-ray based imaging technologies such as computed tomography (CT). Although preclinical CT offers high resolution 3D imaging for bone, accessibility to this modality may be challenging. Learn how optical and high-resolution X-ray imaging capability on the IVIS Lumina X5 system and Living Image® software was used for obtaining high quality images for quantitative analysis in a mouse bone erosion model, with the ease and speed of 2D imaging.
Epifluorescence (2D) imaging of superficially implanted mouse tumor xenograft models offers a fast and simple method for assessing tumor progression or response to therapy. This approach for tumor assessment requires the use of near infrared (NIR) imaging agents specific for different aspects of tumor biology, and this Application Note highlights the ease and utility of multiplex NIR fluorescence imaging to characterize the complex biology within tumors growing in a living mouse.
Targeted cancer therapy aims to block key signaling pathways that are critical for tumor cell growth and survival. The blockage eventually results in cell death via apoptosis and tumor growth suppression. Encouraged by the success in clinical development, many academic and pharmaceutical researcher are in active pursuit of the improvement of next generation targeted anti-cancer drugs. As a result, many new chemical and biological entities are emerging from initial screening of in vitro, in vitro and/or in silico selection processes. From the perspective of drug development, it poses a great challenge on the next stage of in vivo validation and demands a robust, accurate, and efficient method for assessment of these candidates in living animal models.
Optical-based in vivo imaging of vascular changes and vascular leak is an emerging modality for studying altered physiology in a variety of different cancers and inflammatory states. A number of fluorescent imaging probes that circulate with the blood, but have no target selectivity, have been used to detect tumor leakiness as an indication of abnormal tumor vasculature. Inflammation is also characterized by distinct vascular changes, including vasodilation and increased vascular permeability, which are induced by the actions of various inflammatory mediators. This process is essential for facilitating access for appropriate cells, cytokines, and other factors to tissue sites in need of healing or protection from infection. This application note investigates the use of three fluorescent imaging probes, to detect and monitor vascular leak and inflammation in preclinical mouse breast cancer models.
Drug induced liver injury (DILI) is a major reason for late stage termination of drug discovery research projects, highlighting the importance of early integration of liver safety assessment in the drug development process. A technical approach for in vivo toxicology determination was developed using Acetaminophen (APAP), a commonly used over-the-counter analgesic and antipyretic drug, to induce acute hepatocellular liver injury.
In vivo optical imaging can provide information at the cellular biomarker level regarding disease states and therapeutic response. Bioluminescence imaging presents few challenges with respect to imaging and data acquisition. However, fluorescence imaging requires strategies to compensate for background fluorescence. Without proper background subtraction, results may underestimate biological changes or the magnitude of therapeutic efficacy of a drug. There are several contributors to background fluorescence which can vary depending on disease model and probe used all of which need to be considered when developing a mouse model for fluorescence imaging. Learn about key considerations for defining and applying background correction to improve fluorescence quantification and interpretation using the IVIS® platform in this technical note.